News und Analysen
EQS-News: 1&1 AG: Tele Columbus and 1&1 agree wholesale cooperation
EQS-News: 1&1 AG: Tele Columbus and 1&1 agree wholesale cooperation
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: PATRIZIA SE: PATRIZIA announces fresh firepower of up to JPY 150bn (c. EUR 1bn) to invest in Japanese real estate
EQS-News: PATRIZIA SE: PATRIZIA announces fresh firepower of up to JPY 150bn (c. EUR 1bn) to invest in Japanese real estate
EQS-News: Schaeffler AG: Schaeffler strengthens industrial business with acquisition of CERASPIN
EQS-News: Schaeffler AG: Schaeffler strengthens industrial business with acquisition of CERASPIN
EQS-News: Nagarro posts 63.0% YoY revenue growth in Q3 2022, Adjusted EBITDA more than doubles YoY in Q3 2022
EQS-News: Nagarro posts 63.0% YoY revenue growth in Q3 2022, Adjusted EBITDA more than doubles YoY in Q3 2022
EQS-Adhoc: Nagarro SE: Further increase in revenue and margin guidance for FY 2022
EQS-Adhoc: Nagarro SE: Further increase in revenue and margin guidance for FY 2022
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
EQS-News: At the VISION 2045 Summit alongside the COP 27: CEO Stefan Feltens presents SHOP APOTHEKE EUROPE’s NET ZERO 2040 Strategy in Sharm El Sheikh.
EQS-News: At the VISION 2045 Summit alongside the COP 27: CEO Stefan Feltens presents SHOP APOTHEKE EUROPE’s NET ZERO 2040 Strategy in Sharm El Sheikh.
EQS-News: CANCOM: Around 11 percent growth in the third quarter of 2022
EQS-News: CANCOM: Around 11 percent growth in the third quarter of 2022
EQS-News: 1&1 confirms forecast 2022 after the end of the first 9 months
EQS-News: 1&1 confirms forecast 2022 after the end of the first 9 months
EQS-News: GRENKE on the final straight for 2022 after three strong quarters
EQS-News: GRENKE on the final straight for 2022 after three strong quarters
EQS-News: PATRIZIA SE: Weaker markets impact PATRIZIA’s 9M 2022 EBITDA: AUM and recurring management fees still growing but FY 2022 guidance adjusted
EQS-News: PATRIZIA SE: Weaker markets impact PATRIZIA’s 9M 2022 EBITDA: AUM and recurring management fees still growing but FY 2022 guidance adjusted
EQS-News: Krones AG: Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation
EQS-News: Krones AG: Krones expands its capabilities in the growing pharmaceutical market with the acquisition of US company R+D Custom Automation
EQS-News: Schaeffler AG: Further structural measures at Schaeffler
EQS-News: Schaeffler AG: Further structural measures at Schaeffler
EQS-News: Schaeffler AG: Schaeffler delivers encouraging strong 3rd quarter in difficult environment
EQS-News: Schaeffler AG: Schaeffler delivers encouraging strong 3rd quarter in difficult environment
EQS-News: Krones AG: Krones continues profitable growth under difficult conditions
EQS-News: Krones AG: Krones continues profitable growth under difficult conditions
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
EQS-Adhoc: PATRIZIA adapts expectations to changed market environment and lowers its guidance for FY 2022
EQS-Adhoc: PATRIZIA adapts expectations to changed market environment and lowers its guidance for FY 2022
EQS-Adhoc: Fielmann AG: ad hoc announcement for the third quarter
EQS-Adhoc: Fielmann AG: ad hoc announcement for the third quarter
EQS-News: AUTO1 Group SE: AUTO1 Group reports strong Q3 revenue growth and makes significant progress towards profitability
EQS-News: AUTO1 Group SE: AUTO1 Group reports strong Q3 revenue growth and makes significant progress towards profitability
EQS-Adhoc: CANCOM SE: 11 percent revenue growth in Q3 2022 but also higher expenses. New revised annual forecast with target corridors published.
EQS-Adhoc: CANCOM SE: 11 percent revenue growth in Q3 2022 but also higher expenses. New revised annual forecast with target corridors published.
EQS-News: SHOP APOTHEKE EUROPE: SOLID AND SUCCESSFUL QUARTER, FULLY IN LINE WITH GUIDANCE. BETTER MARGINS AND CONTINUED MARKET SHARE GAINS.
EQS-News: SHOP APOTHEKE EUROPE: SOLID AND SUCCESSFUL QUARTER, FULLY IN LINE WITH GUIDANCE. BETTER MARGINS AND CONTINUED MARKET SHARE GAINS.
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors